In Hae Park1, Sun-Young Kong2, Jae Yoon Ro3, Youngmee Kwon1, Joo Hyun Kang4, Hye Jin Mo4, So-Youn Jung1, Seeyoun Lee5, Keun Seok Lee5, Han-Sung Kang1, Eunsook Lee1, Jungnam Joo6, Jungsil Ro7. 1. Center for Breast Cancer, National Cancer Center, Goyang-si, Korea; Breast and Endocrine Center Branch of Research Institute, National Cancer Center, Goyang-si, Korea. 2. Translational Epidemiology Branch, Division of Cancer Epidemiology and Prevention, Research Institute, National Cancer Center, Goyang-si, Korea; Department of Laboratory Medicine, Center for Diagnostic Oncology, Hospital and Research Institute, National Cancer Center, Goyang-si, Korea. 3. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX. 4. Breast and Endocrine Center Branch of Research Institute, National Cancer Center, Goyang-si, Korea. 5. Center for Breast Cancer, National Cancer Center, Goyang-si, Korea. 6. Biometric Research Branch, National Cancer Center, Goyang-si, Korea. 7. Center for Breast Cancer, National Cancer Center, Goyang-si, Korea; Breast and Endocrine Center Branch of Research Institute, National Cancer Center, Goyang-si, Korea. Electronic address: jungsro@ncc.re.kr.
Abstract
BACKGROUND: The immune system might influence breast cancer (BC) prognosis. However, the relationship between programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocyte (TIL) profiles remains unclear with respect to BC subtypes. PATIENTS AND METHODS: We investigated the relationship between TIL profiles for CD8+ and forkhead box P3-positive (FOXP3+) and PD-L1 expression in primary tumor tissue using immunohistochemistry and the clinical outcomes in 2 patient cohorts at the National Cancer Center: 256 patients diagnosed with early-stage BC from January 2001 to December 2005 and 77 hormone receptor (HR)-negative BC patients diagnosed from January 2006 to December 2008. Clinical data were collected, including HR status, human epidermal growth factor receptor 2 expression, disease-free survival, and overall survival (OS). RESULTS: The median patient age was 47 years (range, 28-78), and the median follow-up period was 9.8 years. Of the 333 patients, 186 (55.9%) had HR-positive and 125 (37.5%) had node-positive BC. We found a strong positive correlation between CD8+ TILs and FOXP3+ TILs (P < .001). CD8+ TILs were more abundant in tumors with low PD-L1 expression (P < .001), although no association was found between FOXP3+ TILs and PD-L1 expression. More CD8+ TILs were present in HR-negative than in HR-positive BC (P < .001), and PD-L1 expression was more frequent in HR-positive BC (P < .001). A greater number of CD8+ TILs (increase in quartile) was strongly associated with OS (hazard ratio, 0.61; 95% confidence interval, 0.39-0.95; P = .03) only in HR-negative BC when adjusted for various clinical factors. PD-L1 expression and FOXP3+ TILs did not exhibit such associations. CONCLUSION: Higher CD8+ lymphocyte infiltration was related to lower PD-L1 expression and higher FOXP3+ TIL infiltration in BC. Higher CD8+ TIL expression was associated with prolonged survival only in those with HR-negative BC.
BACKGROUND: The immune system might influence breast cancer (BC) prognosis. However, the relationship between programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocyte (TIL) profiles remains unclear with respect to BC subtypes. PATIENTS AND METHODS: We investigated the relationship between TIL profiles for CD8+ and forkhead box P3-positive (FOXP3+) and PD-L1 expression in primary tumor tissue using immunohistochemistry and the clinical outcomes in 2 patient cohorts at the National Cancer Center: 256 patients diagnosed with early-stage BC from January 2001 to December 2005 and 77 hormone receptor (HR)-negative BC patients diagnosed from January 2006 to December 2008. Clinical data were collected, including HR status, human epidermal growth factor receptor 2 expression, disease-free survival, and overall survival (OS). RESULTS: The median patient age was 47 years (range, 28-78), and the median follow-up period was 9.8 years. Of the 333 patients, 186 (55.9%) had HR-positive and 125 (37.5%) had node-positive BC. We found a strong positive correlation between CD8+ TILs and FOXP3+ TILs (P < .001). CD8+ TILs were more abundant in tumors with low PD-L1 expression (P < .001), although no association was found between FOXP3+ TILs and PD-L1 expression. More CD8+ TILs were present in HR-negative than in HR-positive BC (P < .001), and PD-L1 expression was more frequent in HR-positive BC (P < .001). A greater number of CD8+ TILs (increase in quartile) was strongly associated with OS (hazard ratio, 0.61; 95% confidence interval, 0.39-0.95; P = .03) only in HR-negative BC when adjusted for various clinical factors. PD-L1 expression and FOXP3+ TILs did not exhibit such associations. CONCLUSION: Higher CD8+ lymphocyte infiltration was related to lower PD-L1 expression and higher FOXP3+ TIL infiltration in BC. Higher CD8+ TIL expression was associated with prolonged survival only in those with HR-negative BC.
Authors: Zsófia Pénzváltó; Jane Qian Chen; Clifford G Tepper; Ryan R Davis; Matthew T Silvestrini; Maxine Umeh-Garcia; Colleen Sweeney; Alexander D Borowsky Journal: J Mammary Gland Biol Neoplasia Date: 2019-02-27 Impact factor: 2.673
Authors: Davide Bedognetti; Cristina Maccalli; Salha B J Al Bader; Francesco M Marincola; Barbara Seliger Journal: Breast Care (Basel) Date: 2016-04-26 Impact factor: 2.860
Authors: Marcelo Sobral-Leite; Koen Van de Vijver; Magali Michaut; Rianne van der Linden; Gerrit K J Hooijer; Hugo M Horlings; Tesa M Severson; Anna Marie Mulligan; Nayana Weerasooriya; Joyce Sanders; Annuska M Glas; Diederik Wehkamp; Lorenza Mittempergher; Kelly Kersten; Ashley Cimino-Mathews; Dennis Peters; Erik Hooijberg; Annegien Broeks; Marc J van de Vijver; Rene Bernards; Irene L Andrulis; Marleen Kok; Karin E de Visser; Marjanka K Schmidt Journal: Oncoimmunology Date: 2018-09-11 Impact factor: 8.110
Authors: Yasmine Assadipour; Nikolaos Zacharakis; Jessica S Crystal; Todd D Prickett; Jared J Gartner; Robert P T Somerville; Hui Xu; Mary A Black; Li Jia; Harshini Chinnasamy; Isaac Kriley; Lily Lu; John R Wunderlich; Zhili Zheng; Yong-Chen Lu; Paul F Robbins; Steven A Rosenberg; Stephanie L Goff; Steven A Feldman Journal: Clin Cancer Res Date: 2017-04-04 Impact factor: 12.531
Authors: Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir Journal: Mol Diagn Ther Date: 2022-02-01 Impact factor: 4.074
Authors: Rabia Doğukan; Ramazan Uçak; Fatih Mert Doğukan; Canan Tanık; Bülent Çitgez; Fevziye Kabukcuoğlu Journal: Eur J Breast Health Date: 2019-10-01